Annuncio pubblicitario
Italia markets closed

  • Dow Jones

    39.804,16
    -68,83 (-0,17%)
     

  • Nasdaq

    16.850,90
    +18,28 (+0,11%)
     

  • Nikkei 225

    38.617,10
    -329,83 (-0,85%)
     

  • EUR/USD

    1,0842
    -0,0016 (-0,15%)
     

  • Bitcoin EUR

    64.770,24
    -13,69 (-0,02%)
     

  • CMC Crypto 200

    1.515,29
    -11,13 (-0,73%)
     

  • HANG SENG

    19.195,60
    -25,02 (-0,13%)
     

  • S&P 500

    5.318,92
    -2,49 (-0,05%)
     

Vistin Pharma ASA: Invitation to Q2 2023 conference call

Vistin Pharma ASA
·1 minuto per la lettura
Vistin Pharma ASA
Vistin Pharma ASA

Oslo, Norway, 16 August 2023

Vistin Pharma ASA will release its second quarter and YTD 2023 results on Wednesday 23rd of August 2023. Vistin Pharma will host a conference call for all shareholders and interested parties at the same day; Wednesday 23rd of August at 08:30 CET. There will be a Q&A session following the management discussion.

The conference call will be held in English.

The second quarter conference call will be available via web and audio through the following access points:

Webcast:
https://edge.media-server.com/mmc/p/jokra7jp

Telephone conference (online registration):
https://register.vevent.com/register/BI6600178838a944b187ed120748334f53

ANNUNCIO PUBBLICITARIO

*****

For further information, please contact:

Alexander Karlsen
CFO
+47 97053621
alexander.karlsen@vistin.com


About Vistin Pharma | www.vistin.com

Vistin Pharma is a Norwegian pharmaceutical company producing Metformin Hydrochloride (API). The Metformin is also available as Direct Compressible lubricated granules. As a solely dedicated European Metformin producer, Vistin Pharma is a well-positioned supplier to leading pharmaceutical companies. Vistin Pharma is headquartered in Oslo, Norway, and has highly qualified employees and a dedicated manufacturing facility in Kragerø.